Cancer therapy using bone-seeking isotopes

Lewington, Val

doi:10.1088/0031-9155/41/10/012

Cited by 65 publications

(41 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…This is known in man as a flare response and is seen soon after administration of the radio-pharmaceutical (3 days) 14 . The response is thought to be due to radiation-induced endosseous oedema and is, ironically, regarded as a good prognostic sign since these patients reported dramatic pain relief subsequently 14 . Lewington 14 reported that pain relief is independent of tumour radiosensitivity, and therefore one should be wary of interpreting control of pain as a reflection of the radio-isotope's tumourcidal effect.…”

Section: Discussionmentioning

confidence: 99%

“…It also appears that the diphosphonate, EDTMP, has pharmacological activity that may influence radio-pharmaceutical localisation in neoplastic tissue 14,15 . Dormehl et al 5 found that repeated doses of Sm-153-EDTMP in the baboon led to progressively decreased uptake in normal bone, and this is thought be due to the blocking effect of the diphosphonate EDTMP.…”

Section: Discussionmentioning

confidence: 99%

“…Samarium-153-ethylenediaminetetramethylene phosphonic acid (Sm-153-EDTMP) fulfils these criteria. Samarium-153 is a medium-energy beta-emitting radio-isotope (Ebmax = 0.80 MeV, T = 46.8 h) with a gamma photon (abundance 28 %, KeV 103) coupled to the diphosphonate EDTMP 13,14 . Lattimer et.…”

Section: Introductionmentioning

confidence: 99%

“…Complications of Sm-153-EDTMP treatment are myelotoxicity 1,12,13 and, in some cases, an increase in bone pain following treatment (flare response) 1,14 . Myelotoxicity occurs 1 week after treatment and remains haematologically evident for 2-3 weeks 12,13 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Milner¹,

Dormehl²,

Louw³

et al. 1998

J. S. Afr. Vet. Assoc.

View full text Add to dashboard Cite

Nine dogs with primary bone tumours were treated with Samarium-153-EDTMP (Sm-153- EDTMP). Conventional treatment protocols were precluded by the size of the dogs and the owners' refusal of limb amputation. All the tumours were of the appendicular skeleton; 4 were confirmed osteosarcomas. The other 5 tumours were radiologically suspect for osteosarcoma. Bone scans were performed on all dogs using Technetium-99m-methylene diphosphonate (Tc-99m-MDP) before administration of Sm-153-EDTMP. Regions of interest were identified over the contralateral limb at the same site as the tumour and counts per pixel were recorded for the tumour and contralateral limb and expressed as a ratio. The dogs were given 1 injection of 37 MBq/kg (1 mCi/kg) of Sm-153-EDTMP intravenously. Thoracic and primary tumour site radiographs were taken at monthly or 2-monthly intervals to monitor progression of the primary tumour and search for evidence of metastasis. Two dogs showed no response to treatment, with an increase in bone pain, and were euthanased within 1 month. In 1 dog, a tumour of the scapula underwent complete involution and the dog is considered free of disease at 20 months post Sm-153-EDTMP treatment. The overall tumourcidal effect of a single dose of Sm-153-EDTMP on primary bone tumours was difficult to evaluate in this group of dogs, as, with one exception, all the primary tumours progressed over time and the dogs were euthanased. Pain control, for which Sm-155-EDTMP is used in man, was not evident, except in the dog that responded completely to treatment

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Milner¹,

Dormehl²,

Louw³

et al. 1998

J. S. Afr. Vet. Assoc.

View full text Add to dashboard Cite

show abstract

Neoplasms of the Prostate

Logothetis

Kim

Davis

et al. 2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Cancer of the prostate is the most commonly diagnosed nonskin neoplasm and the second leading cause of cancer‐related mortality in men in the United States. Considerable advances have been made in screening, diagnosis, and therapy options, particularly in advanced disease, but controversies about the diagnosis and management of prostate cancer, especially in the areas of screening and choice of therapy, continue to evolve. Controversies in advanced disease states have shifted from prognostication to prediction, and current treatment considerations are focused on optimization of sequence or combinations of therapy, determining the role of local control and bone targeting. It is anticipated that addressing these knowledge gaps will lead to an integrated and more effective treatment strategies. Further advances in therapy can be achieved by development of new agents with unique mechanisms of action and rational integration into combination therapies. Prostate cancer awareness, clinical application of improved biopsy schemes, and advances in imaging combined with the widespread use of prostate‐specific antigen (PSA) have resulted in increased detection of prostate cancer. The evolving use of the serum PSA concentration and its change over time have not been paralleled by studies that tested the relevance of those findings until the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were first published in 2009. Though many of the apparent discrepancies between these trials can be accounted for by trial design and patient cross‐contamination, they brought to the forefront the dilemma of overdiagnosis and overtreatment and the urgent need to improve the accuracy of clinically significant prostate cancer. It is hoped that replacement of the current morphologic and anatomic classification of prostate cancer with one based on improved understanding of biology will lead to molecular classification and bring closer a personalized management of this complex disease. Salient features that distinguish prostate cancer from other malignancies and that frame the dilemmas surrounding it are its striking age‐dependent incidence, with progressively increasing frequency with increasing age; the variable lethality of morphologically identified cancers; the central role of androgen signaling; and the preponderance of bone‐forming metastases on its lethal progression. The important advances made in each of these areas will, in the near future, modify the approaches currently used to prevent, prognosticate, and treat prostate cancer.

show abstract

Neoplasms of the Prostate

Aparicio¹,

Pilié²,

Surasi³

et al. 2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Cancer of the prostate is the most commonly diagnosed nonskin neoplasm and the second leading cause of cancer‐related mortality in men in the United States. Considerable advances have been made in screening, diagnosis, and therapy options, particularly in advanced disease, but controversies about the diagnosis and management of prostate cancer, especially in the areas of screening and choice of therapy, continue to evolve. Research initiatives in advanced disease have shifted from prognostication to prediction, and current treatment considerations are focused on optimization of therapy sequence, development of rational combinations, biomarker‐driven patient selection, determining the role of local disease control in patients with metastases, and bone targeting therapies. Despite progress, prostate cancer survival has not improved at the same pace as other cancer subtypes. It is anticipated that addressing knowledge gaps will lead to the development of novel agents with unique mechanisms of action and optimization of integrated strategies (surgical, radiation, and medical) to improve overall survival. Prostate cancer awareness, clinical application of improved biopsy schemes, and advances in imaging combined with the widespread use of prostate‐specific antigen (PSA) have resulted in increased detection of early prostate cancer. The question of whether PSA screening would reduce mortality from prostate cancer has now been tested in the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial first published in 2009. Though many of the apparent discrepancies between these trials can be accounted for by trial design and patient cross‐contamination, they brought to the forefront the dilemma of overdiagnosis and overtreatment, as well as the heterogeneous nature of prostate cancer and the urgent need to improve the accuracy of identifying clinically significant early disease with lethal potential. It is hoped that enhancing the current morphologic and anatomic classification of prostate cancer with a better understanding of the molecular underpinnings of diverse disease states will lead to a more refined taxonomy of prostate cancer and ultimately improve outcomes while minimizing treatment‐related morbidity. Salient features that distinguish prostate cancer from other malignancies and frame the dilemmas surrounding it are its striking age‐dependent incidence, with progressively increasing frequency with increasing age, a strong familial and hereditary component, the variable lethality of morphologically identical cancers, the central role of androgen signaling, the preponderance of bone‐forming metastases, and metabolic derangements contributing to lethal progression. Important advances made in each of these areas will modify the approaches currently used to prevent, prognosticate, predict, and treat prostate cancer.

show abstract

Cancer therapy using bone-seeking isotopes

Cited by 65 publications

References 55 publications

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours

Neoplasms of the Prostate

Neoplasms of the Prostate

Contact Info

Product

Resources

About